KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.95

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.

Borje S Andersson, Peter F Thall, Junsheng Ma, Benigno C Valdez, Roland Bassett, Julianne Chen, Sairah Ahmed, Amin Alousi, Qaiser Bashir, Stefan Ciurea, Alison Gulbis, Rita Cool, Jitesh Kawedia, Chitra Hosing, Partow Kebriaei, Steve Kornblau, Alan Myers, Betul Oran, Katayoun Rezvani, Nina Shah, Elizabeth Shpall, Simrit Parmar, Uday R Popat, Yago Nieto, Richard E Champlin

Bone Marrow Transplant 57(8) 1295-1303

PMID35610308
PMCIDPMC9352570
DOI10.1038/s41409-022-01705-7
发表日期2022-05-24
入排依据:Meets all eligibility criteria: Phase III randomized oncology trial in humans with a drug intervention and primary/key secondary time-to-event efficacy endpoint (PFS).
摘要

摘要

Pretransplant conditioning with Fludarabine (Flu)-Busulfan (Bu) is safe, but clofarabine (Clo) has improved antileukemic activity. Hypothesis: Flu+Clo-Bu (FCB) yields superior progression-free survival (PFS) after allogeneic transplantation. We randomized 250 AML/MDS patients aged 3-70, Karnofsky Score ≥80, with matched donors, to FCB (n = 120) or Flu-Bu (n = 130), stratifying complete remission (CR) vs. No CR, (NCR). HCT-CI scores varied, from 0 to 10. All evaluable patients engrafted. Median follow-up was 66 months (interquartile range: 58-80). Three-year relapse incidence (RI), 25% with FCB, vs. 39% with Flu-Bu (p = 0.018), offset by higher non-relapse mortality, 22.6% (95%CI: 16-30.2%) vs. 12.3% (95%CI: 6.5-19%). Three-year PFS was 52% (95%CI: 44-62%) (FCB), vs. 48% (95%CI: 41-58%) (Flu-Bu). FCB benefited CR patients less, NCR patients age ≤ 60 had 3-year 34% RI (95%CI: 19-49%) (FCB) vs. 56% (95%CI: 38-70%) after Flu-Bu (p = 0.037). NCR patients >60 years had 3-year RI 10.0% (FCB), vs. 56.0%, after Flu-Bu (p = 0.003). Bayesian regression analysis including treatment-covariate interactions showed FCB superiority in NCR patients with low HCT-CI (0-2). Serious adverse event profiles were similar for the regimens. Conditioning with FCB did not improve PFS overall, but improved disease control in NCR patients, mandating confirmatory trials. Remission status and HCT-CI should be considered when using FCB.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。